Featured Articles

AstraZeneca and Daiichi Sankyo announced positive interim results from the DESTINY-Breast05 Phase III trial, reinforcing Enhertu’s (trastuzumab deruxtecan) potential as a foundational…
Read More...

Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved its biologic therapy TREMFYA® (guselkumab) for use in children aged six years and older…
Read More...

The U.S. Food and Drug Administration (FDA) has approved Inluriyo (imlunestrant, 200 mg tablets), a new oral treatment from Eli Lilly and Company, for adults with estrogen…
Read More...

AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has accepted their supplemental Biologics License Application (sBLA) for Enhertu…
Read More...

Sanofi Ventures has received an additional $625 million multi-year capital commitment from its parent company, Sanofi, increasing its total assets under management to over $1.4 billion.…
Read More...

Moderna, Inc. has officially opened its Moderna Innovation and Technology Centre (MITC) at the Harwell Science and Innovation Campus in Oxfordshire, UK. This new facility will…
Read More...

Roche has announced positive results from the Phase III evERA study evaluating giredestrant combined with everolimus in patients with estrogen receptor (ER)-positive, HER2-negative,…
Read More...

Roche announced that it has entered into a definitive agreement to acquire 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company developing innovative therapies for…
Read More...

GSK plc announced plans to invest $30 billion in the United States over the next five years, focusing on research and development and supply chain infrastructure. This major investment…
Read More...

Raludotatug deruxtecan (R-DXd), a novel CDH6-targeted antibody-drug conjugate developed by Daiichi Sankyo and Merck, has received Breakthrough Therapy Designation (BTD) from the U.S.…
Read More...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the label of Novo Nordisk’s oral diabetes drug Rybelsus (oral…
Read More...

The Chinese National Medical Products Administration (NMPA) has approved Tzield (teplizumab) as the country’s first disease-modifying therapy for autoimmune type 1 diabetes (T1D). The…
Read More...

Merck, known as MSD outside the U.S. and Canada, announced positive results from its Phase 3 STRIDE-13 trial evaluating CAPVAXIVE, its 21-valent pneumococcal conjugate vaccine, in…
Read More...

Novartis announced it has agreed to acquire Tourmaline Bio, a clinical-stage biopharmaceutical company focused on developing pacibekitug, an anti-IL-6 monoclonal antibody designed to…
Read More...

AbbVie announced that Health Canada has approved ELAHERE® (mirvetuximab soravtansine for injection) under the Priority Review process. ELAHERE is an antibody-drug conjugate (ADC)…
Read More...

Gilead Sciences, Inc. announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's…
Read More...

Amgen has announced plans to invest more than $600 million in a cutting-edge center for science and innovation at its global headquarters in Thousand Oaks, California. The new facility…
Read More...

Boehringer Ingelheim announced that its drug HERNEXEOS (zongertinib tablets) has received approval from China’s National Medical Products Administration (NMPA) as a monotherapy…
Read More...

Novartis has announced encouraging results from its Phase IV V-DIFFERENCE study, which evaluated Leqvio (inclisiran) in patients with high cholesterol who had not met…
Read More...

AbbVie announced that Health Canada has granted a Notice of Compliance (NOC) for RINVOQ (upadacitinib) for the treatment of adults with giant cell arteritis (GCA). The approval includes…
Read More...